Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin(Queen Mary University of London), Christine Katlama(Inserm), Pierre‐Marie Girard, Alex Lund Laursen, Alexander Zoufaly, Sushma Kumar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Norma Porteiro, Ernest Asante‐Appiah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hedy Teppler(United States Military Academy), M. Reyes, Alejandro Afani, Mark Bloch, Khuanchai Supparatpinyo(Chiang Mai University), Valerie Teal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Finlayson, Jean‐Michel Molina(Inserm), Rima Lahoulou(MSD (France)), Pedro Cahn(Fundación Huésped), Johannes Lombaard, Richard Moore, Gustavo Lopardo, Yazdan Yazdanpanah, Havilland Campbell(Merck & Co., Inc., Rahway, NJ, USA (United States)), Graham Smith, Sylvia Hartl, Armin Rieger, Maria Isabel Enriqueta Campos Barker, Hong Wan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhi Jin Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brigitte Schmied, Carolina Eugenia Chahin Anania, Brian Conway(University of British Columbia), James McMahon, David Alfred Baker, Marcelo D Martins, Carlos Perez Cortes, Jan Gerstoft, Philippe Morlat, Anita Rachlis(University of Toronto), Norman Roth, François Raffi, Robert Zangerle, Fiona Smaill, Laurence Slama, Sharon Walmsley, Laurent Cotte(San Francisco General Hospital), Nina Weis
The Lancet HIV
December 20, 2023
Cited by 31


Related Papers